Enable diagnostics tools
and drug development
Diagnosing neurological conditions and creating disease-modifying therapies is complicated enough. Leverage ocular signatures for diagnostic screeners and streamline drug development with eye-tracking biomarkers.
DATASETS AND APPLICATIONS
Scientifically-validated datasets — at your disposal
Parkinson’s DiseaseEssential TremorConcussionMSAPSPLyme Disease
Parkinson’s DiseaseEssential TremorConcussionMSAPSPLyme Disease
EXPEDITE DRUG DEVELOPMENT
Revolutionize diagnostic screening and drug development
Neurological drugs are critical to society — but they also have one of the lowest approval rates out of all pharmaceutical drugs. Neurological drug development often lacks efficacy, target selection and engagement are poor, reliable biomarkers to quantify treatment impact are rare, and studies rely too much on subjective measures.
The solution? HarmonEyes Clinical Biomarkers — a turnkey solution for diagnostics, pharmaceutical, and academic clinical trials, offering objective diagnostic, response, and predictive ocular biomarkers based on eye-tracking data.
Accelerating screening and diagnosis, monitoring disease progression, and predicting diagnoses prior to symptoms are all possible — and easier than ever — with HarmonEyes.
SCREENING AND
DIAGNOSIS UTILITY
Accelerate and improve clinical drug trials
Expedite recruitment, define objective endpoints, and distinguish patients with shared symptomology and comorbidities.
HarmonEyes Clinical Biomarkers helps streamline all phases of clinical drug trials. Get objective diagnostic, response, and predictive ocular biomarkers based on our vast repository of eye-tracking data and enabled by our AI-powered research and modeling platform.
MONITOR DISEASE PROGRESSION
Diagnose and monitor patients with neurological diseases
Stratify neurology patients by disease progression and phenotype.
HarmonEyes Clinical Biomarkers helps you diagnose, classify, and monitor diseases so you can focus on serving patients.
AI-POWERED
AND PATENT-BACKED
Predict a diagnosis prior to symptoms
Neurological diseases can progress slowly. What if you could recognize the presence of one before a patient even exhibits symptoms?
With HarmonEyes Clinical Biomarkers, it’s never been more possible to get ahead of critical neurological diseases, identify treatment protocol, and predict treatment success or failure.
